Antiviral Drugs Market Size, Growth Opportunity 2035

Antiviral Drugs Market - By Drug Class, By Indication, By Type, By Route of Administration, By Age Group, By Distribution Channel - Global Forecast, 2026 – 2035

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research approach

1.3&nbsp;&nbsp;&nbsp; Quality commitments

1.3.1&nbsp;&nbsp;&nbsp; GMI AI policy and data integrity commitment

1.3.1.1&nbsp;&nbsp;&nbsp; Source consistency protocol

1.4&nbsp;&nbsp;&nbsp; Research trail and confidence scoring

1.4.1&nbsp;&nbsp;&nbsp; Research trail components

1.4.2&nbsp;&nbsp;&nbsp; Scoring components

1.5&nbsp;&nbsp;&nbsp; Data collection

1.5.1&nbsp;&nbsp;&nbsp; Partial list of primary sources

1.6&nbsp;&nbsp;&nbsp; Data mining sources

1.6.1&nbsp;&nbsp;&nbsp; Paid sources

1.6.1.1&nbsp;&nbsp;&nbsp; Sources, by region

1.7&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.7.1&nbsp;&nbsp;&nbsp; Revenue share analysis

1.7.2&nbsp;&nbsp;&nbsp; Base year calculation

1.8&nbsp;&nbsp;&nbsp; Forecast model

1.9&nbsp;&nbsp;&nbsp; Research transparency addendum

1.9.1&nbsp;&nbsp;&nbsp; Source attribution framework

1.9.2&nbsp;&nbsp;&nbsp; Quality assurance metrics

1.9.3&nbsp;&nbsp;&nbsp; Our commitment to trust

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&#176; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Drug class trends

2.2.3&nbsp;&nbsp;&nbsp; Indication trends

2.2.4&nbsp;&nbsp;&nbsp; Type trends

2.2.5&nbsp;&nbsp;&nbsp; Route of administration trends

2.2.6&nbsp;&nbsp;&nbsp; Age group trends

2.2.7&nbsp;&nbsp;&nbsp; Distribution channel trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising prevalence of viral infections

3.2.1.2&nbsp;&nbsp;&nbsp; Increasing number of product launches for HIV treatment

3.2.1.3&nbsp;&nbsp;&nbsp; High investment in R&D activities and presence of pipeline products

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing geriatric population

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Emerging drug resistance

3.2.2.2&nbsp;&nbsp;&nbsp; High development cost

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Expansion of personalized antiviral therapies

3.2.3.2&nbsp;&nbsp;&nbsp; Growing adoption of combination and broad spectrum antiviral regimens

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape (Driven by Primary Research)

3.5&nbsp;&nbsp;&nbsp; Pricing analysis (Driven by Primary Research)

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Future market trends (Driven by Primary Research)

3.8&nbsp;&nbsp;&nbsp; Impact of AI and generative AI on the market

3.9&nbsp;&nbsp;&nbsp; Porter’s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2025

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Merger and acquisition

4.6.2&nbsp;&nbsp;&nbsp; Partnership and collaboration

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plan

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class, 2022 – 2035 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Reverse transcriptase inhibitors

5.3&nbsp;&nbsp;&nbsp; DNA polymerase inhibitors

5.4&nbsp;&nbsp;&nbsp; Protease inhibitors

5.5&nbsp;&nbsp;&nbsp; Neuraminidase inhibitors

5.6&nbsp;&nbsp;&nbsp; Other drug classes

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2022 – 2035 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; HIV/AIDS

6.3&nbsp;&nbsp;&nbsp; Hepatitis

6.4&nbsp;&nbsp;&nbsp; Coronavirus infection

6.5&nbsp;&nbsp;&nbsp; Herpes simplex virus (HSV)

6.6&nbsp;&nbsp;&nbsp; Influenza

6.7&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2022 – 2035 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Branded

7.3&nbsp;&nbsp;&nbsp; Generic

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2022 – 2035 ($ Bn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Oral

8.3&nbsp;&nbsp;&nbsp; Parenteral

8.4&nbsp;&nbsp;&nbsp; Topical

8.5&nbsp;&nbsp;&nbsp; Other routes of administration

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2022 – 2035 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Geriatric

9.3&nbsp;&nbsp;&nbsp; Adult

9.4&nbsp;&nbsp;&nbsp; Pediatric

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2022 – 2035 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

10.3&nbsp;&nbsp;&nbsp; Retail pharmacies

10.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 11&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2022 – 2035 ($ Mn)

11.1&nbsp;&nbsp;&nbsp; Key trends

11.2&nbsp;&nbsp;&nbsp; North America

11.2.1&nbsp;&nbsp;&nbsp; U.S.

11.2.2&nbsp;&nbsp;&nbsp; Canada

11.3&nbsp;&nbsp;&nbsp; Europe

11.3.1&nbsp;&nbsp;&nbsp; Germany

11.3.2&nbsp;&nbsp;&nbsp; UK

11.3.3&nbsp;&nbsp;&nbsp; France

11.3.4&nbsp;&nbsp;&nbsp; Italy

11.3.5&nbsp;&nbsp;&nbsp; Spain

11.3.6&nbsp;&nbsp;&nbsp; Netherlands

11.4&nbsp;&nbsp;&nbsp; Asia Pacific

11.4.1&nbsp;&nbsp;&nbsp; China

11.4.2&nbsp;&nbsp;&nbsp; Japan

11.4.3&nbsp;&nbsp;&nbsp; India

11.4.4&nbsp;&nbsp;&nbsp; Australia

11.4.5&nbsp;&nbsp;&nbsp; South Korea

11.5&nbsp;&nbsp;&nbsp; Latin America

11.5.1&nbsp;&nbsp;&nbsp; Brazil

11.5.2&nbsp;&nbsp;&nbsp; Mexico

11.5.3&nbsp;&nbsp;&nbsp; Argentina

11.6&nbsp;&nbsp;&nbsp; Middle East and Africa

11.6.1&nbsp;&nbsp;&nbsp; South Africa

11.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

11.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 12&nbsp;&nbsp;&nbsp;Company Profiles

12.1&nbsp;&nbsp;&nbsp; AbbVie

12.2&nbsp;&nbsp;&nbsp; AstraZeneca

12.3&nbsp;&nbsp;&nbsp; Aurobindo Pharma

12.4&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb

12.5&nbsp;&nbsp;&nbsp; Cipla

12.6&nbsp;&nbsp;&nbsp; Dr. Reddy's Laboratories

12.7&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche

12.8&nbsp;&nbsp;&nbsp; Gilead Sciences

12.9&nbsp;&nbsp;&nbsp; GlaxoSmithKline

12.10&nbsp;&nbsp;&nbsp; Johnson & Johnson

12.11&nbsp;&nbsp;&nbsp; Merck

12.12&nbsp;&nbsp;&nbsp; Novartis

12.13&nbsp;&nbsp;&nbsp; Pfizer

12.14&nbsp;&nbsp;&nbsp; Sun Pharmaceutical

12.15&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical

12.16&nbsp;&nbsp;&nbsp; Viatris

Antiviral Drugs Market

Get a free sample of this report